eCTD Publishing & Validation
HomeServicesFDA SubmissionseCTD Publishing & Validation
Back to FDA Submissions

eCTD Publishing & Validation

Technical Precision for Seamless Review

Overview

A great drug can be delayed by a bad submission format. We handle the technical complexities of electronic Common Technical Document (eCTD) publishing. We ensure your submission is hyperlinked, bookmarked, and validated against the latest FDA criteria, ensuring a smooth technical screening process.

Key Features

Document level publishing (PDF rendering)
XML backbone creation
Hyperlinking and bookmarking
Validation and error resolution

Our Process

1

Source Review

Checking source documents for formatting and legibility.

2

Publishing

Building the eCTD structure and linking documents.

3

Validation

Running validation software to catch and fix errors before submission.

Project Complete & Deliverables Provided

Frequently Asked Questions

eCTD (electronic Common Technical Document) is the mandatory format for submitting applications to the FDA, EMA, and most global regulatory agencies. It standardizes how documents are organized (Modules 1-5), enables hyperlinking between sections, and creates a consistent XML backbone for lifecycle management. FDA has required eCTD for most submissions since May 2017.

Why Choose Us

  • Zero technical refusals
  • Enhanced reviewer navigation
  • Lifecycle management readiness
  • Compliance with e-submission mandates

Get More Details

Request a personalized consultation and detailed information about this service.

Personalized consultation
Detailed service information
Custom timeline & proposal
Request Information

We'll respond within 24 hours

Ready to get started?

Contact our team to discuss your specific needs for eCTD Publishing & Validation.

Schedule Consultation

What Our Clients Say

"We had a last-minute CMC amendment that needed to be published in 48 hours. Adelphi's publishing team worked through the weekend and delivered a clean, validated sequence. No technical issues flagged by FDA."

Sandra Williams

Regulatory Operations Director

Biotech Company